Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 7/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26927004 | 1.00 | TNF (0.44) | TNFHTR6GRM5GRM1PDK4 | |
| SCHEMBL31433761 | 0.91 | TNF (0.39) | TNFHTR6GRM5GRM1PDK4 | |
| SCHEMBL31434030 | 0.91 | TNF (0.39) | TNFHTR6GRM5GRM1PDK4 | |
| SCHEMBL31433535 | 0.91 | TNF (0.39) | TNFHTR6GRM5GRM1PDK4 | |
| SCHEMBL31434035 | 0.89 | TNF (0.38) | TNFGPR119JAK1CDK9CCNT1 | |
| SCHEMBL23541116 | 0.89 | NAMPT (0.41) | HTR6GRM5GRM1PDK4GPR119 | |
| SCHEMBL31282403 | 0.89 | NAMPT (0.41) | HTR6GRM5GRM1PDK4GPR119 | |
| SCHEMBL30026597 | 0.89 | NAMPT (0.41) | HTR6GRM5GRM1PDK4GPR119 | |
| SCHEMBL30731864 | 0.88 | GRM5 (0.41) | HTR6GRM5GRM1PDK4GPR119 | |
| SCHEMBL26924679 | 0.88 | GRM5 (0.41) | HTR6GRM5GRM1PDK4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| WO-2025119380-A1 | ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118067-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025049964-A1 | BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025050016-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119317623-A | Tricyclic quinolone BCL6 bifunctional degradation agents | 树线生物科学公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | TNF 4261/4885HTR6 3252/4885GRM5 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.